Euroespes, S.A.

EEP

ES0133421000

Healthcare Facilities & Services

Market Closed - BME Other stock markets 10:00:21 2024-05-15 EDT			5-day change	1st Jan Change
0.34 ^EUR	0.00%		0.00%	0.00%

2023	Euroespes, S.A. Auditor Raises 'Going Concern' Doubt	CI
2023	Euroespes, S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	CI

EuroEspes, S.A. announced that it expects to receive €15 million in funding

August 31, 2018

EuroEspes, S.A. (BME:EEP) announced a private placement of 53,571,429 shares at a price of €0.28 per share for gross proceeds of €15,000,000 on August 1, 2018.

Latest news about Euroespes, S.A.

Euroespes, S.A. Auditor Raises 'Going Concern' Doubt	23-04-27	CI
Euroespes, S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-27	CI
Euroespes, S.A. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-28	CI
Euroespes, S.A. Reports Earnings Results for the Half Year Ended June 30, 2021	21-10-28	CI
Euroespes, S.A. Reports Earnings Results for the Full Year Ended December 31, 2020	21-04-29	CI
Euroespes, S.A. announced that it has received €4.6 million in funding from Moira Capital Partners	18-11-20	CI
EuroEspes, S.A. announced that it expects to receive €15 million in funding	18-07-31	CI
Ramón Cacabelos, Chairman of the Board of Directors of EuroEspes acquired 3.74% stake in EuroEspes, S.A. to Inversora Portichol S.L.	14-12-01	CI
Tranche Update on EuroEspes, S.A.'s Equity Buyback Plan announced on December 2, 2014.	14-12-01	CI
EuroEspes, S.A. announces an Equity Buyback for 1,075,580 shares, representing 19.37% of its issued share capital.	14-12-01	CI
EuroEspes, S.A.’s Equity Buyback announced on December 2, 2014 has closed with 1,075,580 shares, representing 19.37% of its issued share capital.	14-11-30	CI
EuroEspes, S.A. acquired an additional 50.05% stake in Ebiotec S.A from Inversora Portichol S.L.	14-09-24	CI
EuroEspes, S.A. authorizes a Buyback Plan.	14-06-17	CI

Euroespes SA is a Spain-based company engaged in the healthcare sector. The Company operates a medical center, which focuses on the prevention, diagnosis and treatment of central nervous system disorders, such as Alzheimer and Parkinson, and other common diseases. The Companyâs medical offer includes personalized treatment plans, genomic medicine, epigenetics, neuropsychology, neuro-ophthalmology, digital diagnosis, diagnostic imaging, clinical analysis and nursing services, among others. In addition, it provides pharmacogenetics services and Human Identification Genetics card, which identifies user's deoxyribonucleic acid (DNA) profile. The Company operates through a number of subsidiaries, such as in Euroespes Biotecnologia SA, Distribuidora de Productos SL and Ebiotec Pharma SL.

Sector

Healthcare Facilities & Services

More about the company

Income Statement Evolution

More financial data

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
EUROESPES, S.A.	0.00%	3.98M
CVS HEALTH CORPORATION	-29.08%	70.3B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+2.04%	27.46B
LABORATORY CORPORATION OF AMERICA HOLDINGS	-6.28%	17.8B
FRESENIUS SE & CO. KGAA	+2.32%	17.46B
QUEST DIAGNOSTICS INCORPORATED	+1.97%	15.46B
REDE D'OR SÃO LUIZ S.A.	+7.58%	13.49B
FRESENIUS MEDICAL CARE AG	+10.80%	13.06B
NATERA, INC.	+71.36%	12.96B
TENET HEALTHCARE CORPORATION	+74.90%	12.56B

Other Healthcare Facilities & Services

Euroespes, S.A.

Equities

EEP

ES0133421000

Healthcare Facilities & Services

EuroEspes, S.A. announced that it expects to receive €15 million in funding

Latest news about Euroespes, S.A.

Chart Euroespes, S.A.

Company Profile

Income Statement Evolution

Sector Other Healthcare Facilities & Services